147 related articles for article (PubMed ID: 18043580)
21. New peptides of the polycomb group protein enhancer of zeste homolog 2 with the potential to induce cancer-reactive cytotoxic T lymphocytes in human leukocyte antigen-A2+ prostate cancer patients.
Itoh Y; Komohara Y; Komatsu N; Minami T; Saito K; Noguchi M; Itoh K; Harada M
Oncol Rep; 2007 Nov; 18(5):1231-7. PubMed ID: 17914578
[TBL] [Abstract][Full Text] [Related]
22. Identification of polycomb group protein enhancer of zeste homolog 2 (EZH2)-derived peptides immunogenic in HLA-A24+ prostate cancer patients.
Ogata R; Matsueda S; Yao A; Noguchi M; Itoh K; Harada M
Prostate; 2004 Sep; 60(4):273-81. PubMed ID: 15264237
[TBL] [Abstract][Full Text] [Related]
23. A prostate stem cell antigen-derived peptide immunogenic in HLA-A24- prostate cancer patients.
Matsueda S; Yao A; Ishihara Y; Ogata R; Noguchi M; Itoh K; Harada M
Prostate; 2004 Aug; 60(3):205-13. PubMed ID: 15176050
[TBL] [Abstract][Full Text] [Related]
24. Promiscuous CTL recognition of viral epitopes on multiple human leukocyte antigens: biological validation of the proposed HLA A24 supertype.
Burrows SR; Elkington RA; Miles JJ; Green KJ; Walker S; Haryana SM; Moss DJ; Dunckley H; Burrows JM; Khanna R
J Immunol; 2003 Aug; 171(3):1407-12. PubMed ID: 12874232
[TBL] [Abstract][Full Text] [Related]
25. Induction of cellular and humoral immune responses to tumor cells and peptides in HLA-A24 positive hormone-refractory prostate cancer patients by peptide vaccination.
Noguchi M; Kobayashi K; Suetsugu N; Tomiyasu K; Suekane S; Yamada A; Itoh K; Noda S
Prostate; 2003 Sep; 57(1):80-92. PubMed ID: 12886526
[TBL] [Abstract][Full Text] [Related]
26. Identification of squamous cell carcinoma antigen-derived peptides having the capacity of inducing cancer-reactive CTLs in HLA-A24+ cancer patients.
Homma S; Harada M; Yano H; Ogasawara S; Shichijo S; Matsueda S; Komatsu N; Shomura H; Maeda Y; Sato Y; Todo S; Itoh K
Int J Oncol; 2006 Sep; 29(3):577-87. PubMed ID: 16865273
[TBL] [Abstract][Full Text] [Related]
27. Screening of HLA-A24-restricted epitope peptides from prostate-specific membrane antigen that induce specific antitumor cytotoxic T lymphocytes.
Horiguchi Y; Nukaya I; Okazawa K; Kawashima I; Fikes J; Sette A; Tachibana M; Takesako K; Murai M
Clin Cancer Res; 2002 Dec; 8(12):3885-92. PubMed ID: 12473604
[TBL] [Abstract][Full Text] [Related]
28. New epitope peptides derived from parathyroid hormone-related protein which have the capacity to induce prostate cancer-reactive cytotoxic T lymphocytes in HLA-A2+ prostate cancer patients.
Yao A; Harada M; Matsueda S; Ishihara Y; Shomura H; Takao Y; Noguchi M; Matsuoka K; Hara I; Kamidono S; Itoh K
Prostate; 2005 Feb; 62(3):233-42. PubMed ID: 15389794
[TBL] [Abstract][Full Text] [Related]
29. Identification of erythropoietin receptor-derived peptides having the potential to induce cancer-reactive cytotoxic T lymphocytes from HLA-A24(+) patients with renal cell carcinoma.
Minami T; Minami T; Shimizu N; Yamamoto Y; De Velasco M; Nozawa M; Yoshimura K; Harashima N; Harada M; Uemura H
Int Immunopharmacol; 2014 May; 20(1):59-65. PubMed ID: 24583149
[TBL] [Abstract][Full Text] [Related]
30. Dendritic cells infected with a vaccinia vector carrying the human gp100 gene simultaneously present multiple specificities and elicit high-affinity T cells reactive to multiple epitopes and restricted by HLA-A2 and -A3.
Yang S; Kittlesen D; Slingluff CL; Vervaert CE; Seigler HF; Darrow TL
J Immunol; 2000 Apr; 164(8):4204-11. PubMed ID: 10754316
[TBL] [Abstract][Full Text] [Related]
31. Identification of HLA-A3-restricted cytotoxic T lymphocyte epitopes from carcinoembryonic antigen and HER-2/neu by primary in vitro immunization with peptide-pulsed dendritic cells.
Kawashima I; Tsai V; Southwood S; Takesako K; Sette A; Celis E
Cancer Res; 1999 Jan; 59(2):431-5. PubMed ID: 9927058
[TBL] [Abstract][Full Text] [Related]
32. Identification of parathyroid hormone-related protein-derived peptides immunogenic in human histocompatibility leukocyte antigen-A24+ prostate cancer patients.
Yao A; Harada M; Matsueda S; Ishihara Y; Shomura H; Noguchi M; Matsuoka K; Hara I; Kamidono S; Itoh K
Br J Cancer; 2004 Jul; 91(2):287-96. PubMed ID: 15199397
[TBL] [Abstract][Full Text] [Related]
33. Identification of new melanoma epitopes on melanosomal proteins recognized by tumor infiltrating T lymphocytes restricted by HLA-A1, -A2, and -A3 alleles.
Kawakami Y; Robbins PF; Wang X; Tupesis JP; Parkhurst MR; Kang X; Sakaguchi K; Appella E; Rosenberg SA
J Immunol; 1998 Dec; 161(12):6985-92. PubMed ID: 9862734
[TBL] [Abstract][Full Text] [Related]
34. Identification of hepatitis C virus (HCV) 2a-derived epitope peptides having the capacity to induce cytotoxic T lymphocytes in human leukocyte antigen-A24+ and HCV2a-infected patients.
Wang Y; Takao Y; Harada M; Komatsu N; Ono T; Sata M; Itoh K; Yamada A
Cell Immunol; 2006 May; 241(1):38-46. PubMed ID: 16963008
[TBL] [Abstract][Full Text] [Related]
35. Definition of an HLA-A3-like supermotif demonstrates the overlapping peptide-binding repertoires of common HLA molecules.
Sidney J; Grey HM; Southwood S; Celis E; Wentworth PA; del Guercio MF; Kubo RT; Chesnut RW; Sette A
Hum Immunol; 1996 Feb; 45(2):79-93. PubMed ID: 8882405
[TBL] [Abstract][Full Text] [Related]
36. Phase I trial of a cancer vaccine consisting of 20 mixed peptides in patients with castration-resistant prostate cancer: dose-related immune boosting and suppression.
Noguchi M; Arai G; Matsumoto K; Naito S; Moriya F; Suekane S; Komatsu N; Matsueda S; Sasada T; Yamada A; Kakuma T; Itoh K
Cancer Immunol Immunother; 2015 Apr; 64(4):493-505. PubMed ID: 25662406
[TBL] [Abstract][Full Text] [Related]
37. Immediate early response gene X-1, a stress-inducible antiapoptotic gene, encodes cytotoxic T-lymphocyte (CTL) epitopes capable of inducing human leukocyte antigen-A33-restricted and tumor-reactive CTLs in gastric cancer patients.
Sasada T; Takedatsu H; Azuma K; Koga M; Maeda Y; Shichijo S; Shoumura H; Hirai T; Takabayashi A; Itoh K
Cancer Res; 2004 Apr; 64(8):2882-8. PubMed ID: 15087407
[TBL] [Abstract][Full Text] [Related]
38. Recognition of shared melanoma antigens in association with major HLA-A alleles by tumor infiltrating T lymphocytes from 123 patients with melanoma.
Kawakami Y; Dang N; Wang X; Tupesis J; Robbins PF; Wang RF; Wunderlich JR; Yannelli JR; Rosenberg SA
J Immunother; 2000 Jan; 23(1):17-27. PubMed ID: 10687134
[TBL] [Abstract][Full Text] [Related]
39. Characterization of HLA-A3-restricted cytotoxic T lymphocytes reactive against the widely expressed tumor antigen telomerase.
Vonderheide RH; Anderson KS; Hahn WC; Butler MO; Schultze JL; Nadler LM
Clin Cancer Res; 2001 Nov; 7(11):3343-8. PubMed ID: 11705846
[TBL] [Abstract][Full Text] [Related]
40. Development of a DNA vaccine designed to induce cytotoxic T lymphocyte responses to multiple conserved epitopes in HIV-1.
Wilson CC; McKinney D; Anders M; MaWhinney S; Forster J; Crimi C; Southwood S; Sette A; Chesnut R; Newman MJ; Livingston BD
J Immunol; 2003 Nov; 171(10):5611-23. PubMed ID: 14607970
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]